A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in first-round financing and a lead asset for cancer in preclinical development.

放射性配体疗法（RLTs）领域的新玩家，总部位于挪威和美国的Actithera公司，已带着7550万美元的首轮融资和一个处于临床前开发阶段的癌症主导资产登场。

The proceeds will be used to move the RLT – which targets the cancer antigen fibroblast activation protein (FAP) – into clinical testing in 'multiple indications,' said the company, although it has not given any details of the lead indications or a timeline for those studies.

公司表示，这笔资金将用于推动RLT（靶向癌症抗原成纤维细胞活化蛋白 (FAP)）进入“多个适应症”的临床测试，但并未透露主要适应症的详情或这些研究的时间表。

FAP is found in particular on the 'stroma' of a tumour, an ecosystem of connective tissue and various non-malignant cell types like blood and immune cells that is thought to be involved in the origin and spread of cancers. Its presence tends to be associated with worse clinical outcomes.

FAP 特别存在于肿瘤的“基质”中，基质是结缔组织和各种非恶性细胞类型（如血液和免疫细胞）组成的生态系统，被认为与癌症的起源和扩散有关。它的存在往往与较差的临床结果相关。

The protein has attracted interest both as a way to diagnose and image tumours and as a target for radiopharmaceuticals that can direct cell-killing radiotherapy to them, reducing the risk of off-target side effects.

该蛋白质作为一种诊断和成像肿瘤的方法以及作为将放射治疗导向肿瘤的放射性药物的靶点，引起了人们的兴趣，这可以减少脱靶副作用的风险。

Biopharma companies have been trying to develop drugs that target FAP for some time, including Roche, which has taken multiple candidates into the clinic but also chalked up a string of failed programmes. That list includes fusion protein simlukafusp alfa, which reached phase 2 before being dropped..

生物医药公司一直在尝试开发针对FAP的药物，其中包括罗氏，该公司已将多个候选药物推进到临床阶段，但也遭遇了一系列失败的项目。这份清单包括融合蛋白simlukafusp alfa，该药物在进入二期临床后被放弃。

On the radiopharma front, Actithera is entering a category that already has a number of players, notably

在放射性药物领域，Actithera正在进入一个已经有多个竞争者的类别，特别是

Novartis

诺华

, which has licensed diagnostic and therapeutic candidates from 3B Pharma and iTheranostics, as well as

，该公司已从3B Pharma和iTheranostics获得诊断和治疗候选药物的许可，以及

Noria Therapeutics

诺瑞亚治疗学

, which is partnered with Lantheus on a FAP-targeting imaging agent, and Eli Lilly with

，该公司与Lantheus合作开发了一种针对FAP的成像剂，并与礼来公司合作。

PNT2004

PNT2004

, an early clinical-stage therapeutic acquired when it bought Point Biopharma in 2023.

，这是一种在2023年收购Point Biopharma时获得的早期临床阶段治疗药物。

Other players, meanwhile, include Philogen, Jiangsu HengRui, and Chengdu New Radiomedicine, which all have candidates in early-stage clinical development.

其他参与者还包括 Philogen、江苏恒瑞和成都新放射医学，这些公司都有处于早期临床开发阶段的候选药物。

Actithera's take on the RLT category is the development of small-molecule radioligands that can overcome current challenges in radiopharma development, including targeting delivery specifically to the site of the cancer, achieving long tumour residence times, and rapidly clearing the RLT from the body to reduce toxicity..

Actithera对RLT类别的看法是开发小分子放射配体，以克服放射药物开发中的当前挑战，包括将目标特异性递送至癌部位、实现长肿瘤滞留时间，并快速从体内清除RLT以减少毒性。

The company reckons its FAP candidate offers 'best-in-class potential due to its optimal pharmacokinetic profile and tumour specificity.'

该公司认为，其FAP候选药物因具有“最佳药代动力学特性和肿瘤特异性”，而拥有“同类最佳的潜力”。

The Oslo and Cambridge, Massachusetts-based company was founded by former EMD Serono executive Dr Andreas Goutopolous, a medicinal chemist by training who will also serve as its chief executive.

总部位于奥斯陆和马萨诸塞州剑桥的公司由前EMD Serono高管安德烈亚斯·古托波洛斯博士创立，他是一名药物化学家，也将担任该公司的首席执行官。

'We set out to bring structure-based and kinetics-driven thinking from small-molecule drug design into the world of radiopharmaceuticals,' he said. 'We engineer our radioconjugates for extended retention within tumours, making them ideally suited for longer-lived radionuclides and ultimately delivering more convenient dosing schedules and enhanced efficacy and safety for patients.'.

“我们着手将基于结构和动力学驱动的小分子药物设计思维引入放射性药物领域，”他说道。“我们设计的放射性结合物能够在肿瘤内长时间滞留，使它们非常适合用于寿命更长的放射性核素，最终为患者提供更便捷的给药方案，并增强疗效和安全性。”

The Series A was co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital, with a syndicate that also included Bioqube Ventures, Surveyor Capital, and others.

A轮融资由创始投资者M Ventures和新领投方Hadean Ventures、Sofinnova Partners及4BIO Capital共同领投，参与投资的财团还包括Bioqube Ventures、Surveyor Capital等。